The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App 
Professionals >> Visit The Body PROThe Body en Espanol
Ask the Experts About

Choosing Your MedsChoosing Your Meds
Rollover images to visit our other forums!
Recent AnswersAsk a Question
  • Email Email
  • Glossary Glossary


Jul 31, 2007

Hello, I have almost one year taking Kaletra and Truvada. does this treatment would cause lipodystrophia? How can I avoid it if the case? My doctor is thinking on changing my treatment to Reyataz, Ritonavir and truvada. Is that any better for the Lipodystrophia?

Response from Dr. Young

Thank you for your post.

Lipodystrophy probably has multiple causes or risk factors- some are related to HIV medications, others related to HIV itself (ie., how low your CD4 count was before starting medications), race or gender.

Among the nuke medications, the components of Truvada (tenofovir, FTC) are not thought to be associated with excess (or added) risk of lipodystrophy. Surprisingly, recent data from the ACTG5142 study suggests that Kaletra (lopinavir/ritonavir) is also associated with lower risk than very commonly prescribed non-nuke, Sustiva (efavirenz).

There's little to suggest (though many believe this) that Reyataz would do any better with regard to lipo risk.

Hope this helps, BY


  • Email Email
  • Glossary Glossary

 Get Email Notifications When This Forum Updates or Subscribe With RSS



This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.

Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.

Review our complete terms of use and copyright notice.

Powered by ExpertViewpoint